Videos

Jennifer R. Brown, MD, PhD, highlights newly FDA approved Bruton’s tyrosine kinase inhibitor (BTKi) monotherapy therapies for the treatment of CLL (chronic lymphocytic leukemia).

Expert perspectives on the use of frontline BTKi (Bruton's tyrosine kinase inhibitors) monotherapy in the treatment of chronic lymphocytic leukemia (CLL).

A leading authority in multiple myeloma comments on the future of belantamab mafodotin, such as combination therapy based on the DREAMM 5 and DREAMM 8 trials.

Sagar Lonial, MD, FACP, emphasizes the importance of partnering with eye care specialists to manage optical toxicities of patients taking belantamab mafodotin.

A key opinion leader in medical oncology reviews optical and hematological toxicities of belantamab mafodotin and discusses how to mitigate adverse events.

An expert in multiple myeloma considers rationale for targeting BCMA and discusses recent FDA approval of belantamab mafodotin based on the DREAMM 2 trial.

Sagar Lonial, MD, FACP, discusses factors to consider when selecting later lines of therapy for patients with triple-class refractory multiple myeloma (MM).

Sagar Lonial, MD, FACP, discusses the FDA’s recent accelerated approval of belantamab mafodotin for patients with triple-class refractory multiple myeloma (MM) and considers best practices for managing ocular toxicities.

Robert J. Motzer, MD, provides perspective on recent data from the phase 3 CLEAR trial (Study 307)/KEYNOTE-581 for advanced renal cell carcinoma.

A comprehensive review of the efficacy and safety data from the phase 3 CLEAR trial (Study 307/KEYNOTE-581) for the frontline treatment of advanced renal cell carcinoma.

An expert in genitourinary oncology, Robert J. Motzer, MD, reviews the recent historic advances in frontline combinations for the treatment of advanced clear-cell renal cell carcinoma.

Tycel J. Phillips, MD, discusses the design and responses at 8 weeks in a phase 2 trial of parsaclisib in patients with relapsed/refractory marginal zone lymphoma.

The future of ovarian cancer treatment is discussed through a summary of current treatment options, future directions, and a review the unmet needs facing patients and physicians today.

Shannon Westin, MD, reviews essential treatment considerations for physicians when subscribing niraparib.

The utilization and effectiveness of using PARP inhibitors in treating ovarian cancer is considered.

Shannon Westin, MD, discusses niraparib and its relation to the design, efficacy, and practical implications of the PRIMA trial.

Systemic frontline therapy options are explored through the lens of treating ovarian cancer.

Shannon Westin, MD, analyzes the role of molecular testing in newly diagnosed ovarian cancer.

Shannon Westin, MD, discusses the prognosis of the case patient and the general prognosis and treatment options for ovarian cancer patients overall.

Shannon Westin, MD, introduces the case patient and highlights the diagnosis and treatment path to combat stage IV ovarian cancer.

Shannon Westin, MD, analyzes the diagnosis and treatment of a 68-year-old woman with recurrent ovarian cancer.

Bradley McGregor, MD, discusses the ongoing COSMIC-313 trial of cabozantinib, ipilimumab, and nivolumab in patients with renal cell carcinoma.

David S. Hong, MD, of The University of Texas MD Anderson Cancer Center, shares his enthusiasm for ongoing research efforts to optimize treatment for patients with advanced solid tumors who harbor NTRK gene fusions.

Important takeaways from recent safety and efficacy data presented on the use of larotrectinib as treatment for advanced differentiated and anaplastic thyroid cancers with NTRK gene fusions.

Dr David S. Hong reacts to updated survival data associated with the use of larotrectinib as treatment for TRK fusion–positive non–small cell lung cancer.

The significance of recent data exploring larotrectinib, a TRK inhibitor, in a subset of patients with TRK fusion–positive tumors with CNS (central nervous system) metastasis.

David S. Hong, MD, of The University of Texas MD Anderson Cancer Center, discusses the availability of TRK inhibitors to treat advanced TRK fusion-positive solid tumors, highlighting their safety and efficacy.

Current preferences for testing patients with advanced solid tumors for NTRK gene fusions to help guide therapy based on treatment advances for TRK fusion-positive solid tumors.

David S. Hong, MD, of the University of Texas MD Anderson Cancer Center, reacts to the growing interest around identifying NTRK gene fusions in various solid tumor types and treating appropriate patients with oral TRK inhibitors.

Eric Pujade-Laurine, MD, PhD, discusses the importance of homologous recombination repair deficiency (HRD) testing to provide prognostic information and detect BRCA mutations in platinum-sensitive relapsed ovarian cancer.